96 related articles for article (PubMed ID: 11296986)
1. Termination of disease modifying antirheumatic drugs in psoriatic arthritis.
Ujfalussy I; Koó E; Seszták M
J Rheumatol; 2001 Mar; 28(3):682-3. PubMed ID: 11296986
[No Abstract] [Full Text] [Related]
2. Termination of disease modifying antirheumatic drugs in psoriatic arthritis.
Lacaille D; Stein HB; Raboud J; Klinkhoff AV
J Rheumatol; 2002 Apr; 29(4):860-1. PubMed ID: 11950038
[No Abstract] [Full Text] [Related]
3. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
Ujfalussy I; Koó E; Seszták M; Gergely P
Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
[TBL] [Abstract][Full Text] [Related]
4. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
Nikas SN; Voulgari PV; Takalou IP; Katsimbri P; Drosos AA
Ann Rheum Dis; 2005 Nov; 64(11):1665-7. PubMed ID: 16227426
[No Abstract] [Full Text] [Related]
5. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
[No Abstract] [Full Text] [Related]
6. Transient and slight thrombocytopaenia induced by etanercept during treatment of psoriatic arthritis.
Stinco G; Piccirillo F; Patrone P
Acta Derm Venereol; 2008; 88(3):281-2. PubMed ID: 18480934
[No Abstract] [Full Text] [Related]
7. [Spondyloarthritis including psoriatic arthritis].
Krause A; Märker-Hermann E
Dtsch Med Wochenschr; 2012 Oct; 137(40):2031-3. PubMed ID: 23023616
[No Abstract] [Full Text] [Related]
8. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
9. Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment.
Gómez-Vaquero C; Rodríguez-Moreno J; Ros S; Marcos R; Fiter J; Roig-Escofet D
Br J Rheumatol; 1996 Jun; 35(6):564-7. PubMed ID: 8670578
[TBL] [Abstract][Full Text] [Related]
10. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
Helliwell PS; Taylor WJ;
J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
[TBL] [Abstract][Full Text] [Related]
11. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
12. Treatment of psoriatic arthritis.
Williamson L; Dockerty JL; Dalbeth N
Rheumatology (Oxford); 2004 Jul; 43(7):938-9. PubMed ID: 15213344
[No Abstract] [Full Text] [Related]
13. Long term treatment of psoriatic arthritis with infliximab.
Yazdani-Biuki B; Wohlfahrt K; Mulabecirovic A; Mueller T; Hermann J; Graninger WB; Brezinschek HP; Brezinschek RI
Ann Rheum Dis; 2004 Nov; 63(11):1531-2; author reply 1532. PubMed ID: 15479917
[No Abstract] [Full Text] [Related]
14. [Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept].
Mrowietz U; Barth J; Boehncke WH; Rosenbach T; Wozel G
J Dtsch Dermatol Ges; 2005 Jun; 3(6):470-2. PubMed ID: 15892851
[No Abstract] [Full Text] [Related]
15. Acute injection site reaction to intraarticular etanercept administration.
Arnold EL; Khanna D; Paulus H; Goodman MP
Arthritis Rheum; 2003 Jul; 48(7):2078-9. PubMed ID: 12847708
[No Abstract] [Full Text] [Related]
16. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
Cisternas M; Gutiérrez M; Jacobelli S
Arthritis Rheum; 2002 Nov; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
[No Abstract] [Full Text] [Related]
17. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.
Cauza E; Cauza K; Hanusch-Enserer U; Etemad M; Dunky A; Kostner K
Wien Klin Wochenschr; 2002 Dec; 114(23-24):1004-7. PubMed ID: 12635469
[TBL] [Abstract][Full Text] [Related]
18. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
[TBL] [Abstract][Full Text] [Related]
19. [Etanercept].
Mühlhäuser U; Münzel F; Eschenhagen T
Dtsch Med Wochenschr; 2003 Aug; 128(34-35):1775-8. PubMed ID: 12934172
[No Abstract] [Full Text] [Related]
20. Long term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radiographic response.
Rinaldi F; Provenzano G; Termini A; Spinello M; La Seta F
Ann Rheum Dis; 2005 Sep; 64(9):1375-6. PubMed ID: 16100346
[No Abstract] [Full Text] [Related]
[Next] [New Search]
